Xinrong Xiang

P.R. China
Chengdu, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Correction to "Rational Design of a Novel Class of Human ClpP Agonists through Ring-Opening Strategy with Enhanced Antileukemia Activity".

Correction to "Rational Design of a Novel Class of Human ClpP Agonists through Ring-Opening Strategy with Enhanced Antileukemia Activity".

Journal: Journal of medicinal chemistry
Published: December 03, 2025

CSF3R Mutations Imply Adverse Prognostic Impact in Adult Acute Myeloid Leukemia Patients: A Single-Center Retrospective Study.

CSF3R Mutations Imply Adverse Prognostic Impact in Adult Acute Myeloid Leukemia Patients: A Single-Center Retrospective Study.

Journal: Cancer medicine
Published: September 05, 2025

ASAH1-mediated sphingolipid metabolic reprogramming in venetoclax resistance of AML: beyond the monocytic phenotypes.

ASAH1-mediated sphingolipid metabolic reprogramming in venetoclax resistance of AML: beyond the monocytic phenotypes.

Journal: BMC cancer
Published: May 12, 2025

Myelodysplastic Neoplasms (MDS): Pathogenesis and Therapeutic Prospects.

Myelodysplastic Neoplasms (MDS): Pathogenesis and Therapeutic Prospects.

Journal: Biomolecules
Published: March 30, 2025

Chidamide and cytarabine synergistically treat acute myeloid leukemia: inhibiting ribosome biogenesis via the MYC-RRP9 pathway.

Chidamide and cytarabine synergistically treat acute myeloid leukemia: inhibiting ribosome biogenesis via the MYC-RRP9 pathway.

Journal: Cell death & disease
Published: January 17, 2025

The diagnostic value and clinical correlations of bone marrow supernatant S100A8 and S100A9 in myelodysplastic neoplasms.

The diagnostic value and clinical correlations of bone marrow supernatant S100A8 and S100A9 in myelodysplastic neoplasms.

Journal: Cytokine
Published: August 31, 2024

Discovery of 5-(Piperidin-4-yl)-1,2,4-oxadiazole Derivatives as a New Class of Human Caseinolytic Protease P Agonists for the Treatment of Hepatocellular Carcinoma.

Discovery of 5-(Piperidin-4-yl)-1,2,4-oxadiazole Derivatives as a New Class of Human Caseinolytic Protease P Agonists for the Treatment of Hepatocellular Carcinoma.

Journal: Journal of medicinal chemistry
Published: June 21, 2024

Rational Design of a Novel Class of Human ClpP Agonists through a Ring-Opening Strategy with Enhanced Antileukemia Activity.

Rational Design of a Novel Class of Human ClpP Agonists through a Ring-Opening Strategy with Enhanced Antileukemia Activity.

Journal: Journal of medicinal chemistry
Published: April 15, 2024

Discovery of a Novel Series of Homo sapiens Caseinolytic Protease P Agonists for Colorectal Adenocarcinoma Treatment via ATF3-Dependent Integrated Stress Response.

Discovery of a Novel Series of Homo sapiens Caseinolytic Protease P Agonists for Colorectal Adenocarcinoma Treatment via ATF3-Dependent Integrated Stress Response.

Journal: Journal of medicinal chemistry
Published: February 08, 2024

Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study.

Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study.

Journal: Annals of hematology
Published: December 07, 2023

Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties.

Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties.

Journal: Science translational medicine
Published: April 05, 2023

Differentiation therapy using low-dose venetoclax in a variant acute promyelocytic leukaemia carrying ZBTB16-RARA.

Differentiation therapy using low-dose venetoclax in a variant acute promyelocytic leukaemia carrying ZBTB16-RARA.

Journal: British journal of haematology
Published: August 10, 2022
Showing 1-12 of 16

Last Updated: 09/26/2026